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Abstract
We have modified the periplasmic Escherichia coli glucose/galactose binding protein (GBP)
and labelled with environmentally sensitive fluorophores to further explore its potential as a
sensor for the evaluation of glucose concentration in airway surface liquid (ASL). We identi-
fied E149C/A213R GBP labelled with N,N’-Dimethyl-N-(iodoacetyl)-N’-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)ethylenediamine (IANBD, emission wavelength maximum 536nm) with a Kd
for D-glucose of 1.02mM and a fluorescence dynamic range of 5.8. This sensor was specific
for D-glucose and exhibited fluorescence stability in experiments for several hours. The use
of E149C/A213R GBP-IANBD in the ASL of airway cells grown at air-liquid-interface (ALI)
detected an increase in glucose concentration 10 minutes after raising basolateral glucose
from 5 to 15mM. This sensor also reported a greater change in ASL glucose concentration
in response to increased basolateral glucose in H441 airway cells compared to human bron-
chial epithelial cells (HBEC) and there was less variability with HBEC data than that of H441
indicating that HBEC more effectively regulate glucose movement into the ASL. The sensor
detected glucose in bronchoalveolar lavage fluid (BALf) from diabetic db/db mice but not
normoglycaemic wildtype mice, indicating limited sensitivity of the sensor at glucose con-
centrations <50μM. Using nasal inhalation of the sensor and spectral unmixing to generate
images, E149C/A213R GBP-IANBD fluorescence was detected in luminal regions of cryo-
sections of the murine distal lung that was greater in db/db than wildtype mice. In conclusion,
this sensor provides a useful tool for further development to measure luminal glucose con-
centration in models of lung/airway to explore how this may change in disease.
Introduction
The development of molecular sensors that respond to real-time changes in the concentration
of intra- and extracellular molecules has rapidly increased. Sensors that measure Ca2+ [1],
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We previously employed the periplasmic Escherichia coli glucose/galactose binding protein
(GBP) labelled with environmentally sensitive fluorophores to investigate its potential as a glu-
cose sensor for the evaluation of glucose concentration in airway surface liquid (ASL). This
liquid lines the luminal surface of the airways. In the distal lung the depth of fluid is <1μm,
increasing to approximately 7μm in the upper airways and further in nasal secretions. Thus,
to estimate glucose concentrations of ASL in vivo generally uses secretions that are accessible
(eg. nasal, bronchial) or techniques such as bronchoalveolar lavage (BAL; which significantly
dilutes ASL) or exhaled breath condensate (of which only a small fraction is derived from
ASL). In vitro, the depth of ASL generated by airway epithelial cells grown at air-liquid-inter-
face remains ~7μm. Thus direct measurement of glucose in ASL remains challenging [4]. Nev-
ertheless, using such techniques, the normal concentration of glucose in ASL (in vitro and in
vivo) was measured as ~0.4 mM [5–8]. However, exposure to pro-inflammatory stimuli (e.g.
in respiratory disease) or hyperglycaemia (e.g. diabetes mellitus) increased glucose concentra-
tion. When both are present, (e.g. Cystic Fibrosis-related diabetes) glucose concentration in
the ASL was shown to reach ~4 mM [5]. This rise in glucose was associated with increased
presence of respiratory pathogens such as methicillin-resistant Staphylococcus aureus and
Pseudomonas aeruginosa [9,10]. The measurement of ASL glucose concentration in situ,
particularly in the lower airways, and the measurement of dynamic changes in ASL glucose
concentration in response to hyperglycaemic/pro-inflammatory challenge remain difficult
because of the low volume and inaccessibility of samples. Measurement of glucose in ASL
using fluorescent GBPs therefore provides a potential solution.
GBP alters its conformation when glucose binds and when linked to an environmentally-
sensitive fluorophore it permits glucose binding to be detected as a change in fluorescence.
GBP has previously been used as a core for several fluorescent glucose biosensors [11–13]. The
original GBP has a Kd for D-glucose of approximately 0.8 μM [14]. Therefore, we introduced
mutations H152C/A213R to decrease the affinity for D-glucose, in order to obtain a sensor
with a Kd (~1mM) to be able to measure glucose concentration in ASL. The mutated GBP
linked to the fluorophore BADAN gave the most useful Kd and the biggest dynamic range. It
also had a clear specificity for D-glucose. However, the wavelength of BADAN was too low for
effective ex vivo/in vivo imaging. Linking the H152C/A213R GBP to IANBD increased the Kd
for D-glucose to an unusable 25 mM and longer wavelength fluorophores Blue oxazine, Nile
Blue and Chromis 678 had very limited dynamic range.
We hypothesised that several other mutations could be utilised to obtain a GBP linked to a
longer wavelength fluorophore, with an appropriate Kd and dynamic range for D-glucose. We
have explored these mutations and identified a new candidate GBP which can be used to effec-
tively measure glucose concentration in ASL overlying airway epithelial cells in vitro, the pres-
ence of raised glucose in ex vivo BALf and could be developed further for in vivo imaging.
Materials and methods
Point-mutation polymerase chain reaction (PCR)
C-terminal His tagged pET303-GBP plasmid was a kind gift of Dr Faaziah Khan (Kings Col-
lege London). Site-directed mutagenesis primers were designed using QuickChange primer
design online (Agilent Genomics) (Table 1). Site-directed mutagenesis primers (0.2 μM) were
added to 100 ng of pET303-GBP template DNA, 2.5 units of DNA polymerase PfuUltra II, 0.8
mM dNTP, 17% DMSO in PfuUltra II buffer (Agilent technologies) and subjected to 18 cycle
PCR with denaturation 95˚C for 50 secs, annealing 60˚C for 50 secs and elongation at 68˚C for
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7 mins. Methylated template DNA was digested with DpnI (20 units; New England Biolabs)
overnight at 37˚C. The DNA was transformed into XL10 E. coli and plasmids extracted using a
using a QIAGEN HiSpeed Plasmid Midi kit (Qiagen, Venlo, Netherlands). Mutations were
confirmed by sequencing (Beckman Coulter genomics).
GBP protein expression and purification
Plasmids were transformed into E. coli BL21 DE3 Gold (Agilent Technologies). Bacteria were
grown at 37˚C, 225 rpm in Lennox LB broth plus 50 μg/ml ampicillin until the OD600nm was
between 0.4–0.6. Protein expression was induced with 0.5 mM isopropyl-beta-D-thiogalacto-
pyranoside (IPTG) overnight at 20˚C. E. coli were then pelleted and lysed using 1 mg/ml lyso-
zyme plus sonication. The sample was then centrifuged at 11,000 rpm, 4˚C for 60 minutes and
the supernatant applied to a nickel nitrilotriacetic acid (Ni-NTA) (Qiagen) column. The pro-
tein was eluted in 1.5 ml fractions. 15 μl of each fraction was subjected to SDS-PAGE analysis
using 4–12% Bis-Tris gel (Life Technologies) to confirm the presence of the 35kDa GBP.
Protein concentration was determined using a Nanodrop 1000 spectrophotometer (Thermo
Scientific).
Labelling proteins with fluorophores
Purified proteins were labelled with environmentally sensitive fluorophores (Table 2), either
6-Bromoacetyl-2-Dimethylaminonaphthalene (BADAN) (Thermo Fisher) or N,N’-Dimethyl-
N-(iodoacetyl)-N’-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD) (Life Tech-
nologies) by combining 100 μM protein, 50 μM tris(2-carboxyethyl)phosphine (TCEP),
500 μM fluorophore and PBS to a volume of 500 μl and incubating on ice overnight at 4˚C.
The protein was then dialysed in PBS using 12kDa dialysis pods (Spectrum Labs) overnight at
4˚C. Proteins labelled with Nile blue or Chromis 678 utilised click chemistry. GBP-alkyne was
obtained by incubating 100 μM of GBP with 10-fold excess of iodoacetamide alkyne in PBS,
2.5 mM TCEP, pH 7.4, for 2 h at room temperature. Excess of alkyne was removed by exten-
sive dialysis in PBS pH 7.4 at 4˚C (Slide-a-Lyser 10 kDa, Pierce). This was then incubated with
the dye-azide using the Click-iT1 Protein Reaction Buffer kit for 1 h at room temperature.
Table 1. Site directed mutagenesis primers.








Table 2. Fluorophores attached to glucose binding protein mutants and their respective excitation and emission
wavelengths.
Fluorophore Excitation (nm) Emission (nm)
BADAN 387 535
IANBD 480 536
Nile blue azide 625 670
Chromis 678 azide 677 701
https://doi.org/10.1371/journal.pone.0254248.t002
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The excess of dye was removed by extensive dialysis as above. Dye protein conjugate concen-
trations are reported as protein concentration.
Equilibrium glucose binding
Equilibrium glucose binding curves were obtained by continuous titration followed by correc-
tions for dilution and photobleaching. To determine the dynamic range (Fmax/F0), the coop-
erativity (n) and the dissociation constant for D-glucose (Kd) of the labelled GBP proteins,
glucose affinity assays were performed using an automated syringe pump (ALADDIN 1000,
WPI). Labelled GBP proteins (40–100 nM) were titrated continuously with Glucose at 10–
20 μL/min flow rate in a stirred 3 mL cuvette, in PBS pH 7.4. Fluorescence was measured at
fluorophore excitation and emission wavelength peaks (Table 2) at 20˚C on a Fluorolog3
spectrofluorimeter (Horiba Scientific). Data were expressed as the mean of triplicates ± SEM.
The fluorescence changes were normalised and fitted to the Hill equation Y = Bmax�X^n/
(Kd^n + X^n) using Prism GraphPad 6 software. As GBP/glucose buinding should not exhibit
co-operativity h was constrained to�1.
Airway epithelial cells
H441 airway epithelial cell line was obtained from ATCC. Human bronchiolar epithelial cells
HBECs were obtained by the UNC Marsico Tissue Culture Core from endobronchial brush-
ings or extracted from explanted normal lungs as previously described. Human Subject
Research Ethical approvals were granted by The University of North Carolina at Chapel Hill
Biomedical Institutional Review Board (protocol #03–1396) [22]. H441 and HBEC were trans-
ferred onto transwell permeable supports (Costar) and grown at air-liquid-interface (ALI) to
form confluent monolayers as previously described [10]. For studies of glucose in airway sur-
face liquid (ASL), cells were transferred into basolateral HEPES buffered Kreb’s solution
(HEPES 24 mM, NaCl 101 mM, NaHCO3 12 mM, MgCl2 1.2 mM, CaCl2.2H2O 1.2 mM, KCl
5.2 mM) with either 5 mM D-glucose + 10 mM L glucose or 15 mM D-glucose.
ASL fluorescence analysis
E149C/A213R GBP-IANBD (20μl of 0.3μM) or vehicle control was added to the apical surface
of H441 or HBEC grown at ALI with known concentrations of D-glucose (to obtain a dose
response) or without glucose (to estimate glucose concentration in the ASL) and allowed to
equilibrate for 10 minutes at 37˚C in a humidified incubator. Fluorescent output was read by
a TECAN infinite F200 PRO plate reader excitation/emission 485/535nm. The fluorescence
emission of IANBD or vehicle control was analysed from 9 points within the Transwell (points
were taken a minimum of 7.5mm from the edge of the well). Settings were optimised differ-
ently for H441 and HBEC due to the differences in monolayer thickness and ASL heights in
these cell types. Vehicle control background values were subtracted from sensor fluorescent
outputs to obtain values for E149C/A213R GBP-IANBD fluorescence. For time course studies
emission intensity was collected every minute for the first 10 minutes, followed by readings
every 10 minutes up to an hour, then every hour until 5 hours had elapsed. Alternatively,
E149C/A213R GBP-IANBD was added together with 20μl 0.5 mg/ml of 10 kDa dextran-tetra-
methylrhodamine (TMR; Life Technologies, USA) as a labelling control for the ASL. Cells
were labelled with nuclear stain Hoechst 33342. Images were acquired in XZ-scanning mode
by using a Leica SP8 confocal microscope with a ×63/1.3 numerical aperture (NA) glycerol
immersion lens. Cells were exposed to either 5mM D- + 10mM L-glucose or 15mM D- glucose
basolaterally for 10 minutes before imaging. Image intensities were analysed using ImageJ soft-
ware (NIH).
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Bronchoalveolar lavage glucose measurements
9-week-old C57B/6 and BKS.Cg-m+/+Leprdb/J (db/db) (6 of each group) mice were termi-
nated with a single lethal intraperitoneal injection of 0.2 mL pentobarbital (60 mg/ml) diluted
1:1 with saline. Prior to termination, blood was collected from the vena saphena of the hin-
dlimb, and blood glucose was measured with an Accu-Chek1Mobile meter (Roche). The
trachea was exposed and a catheter inserted between two cartilage rings. The catheter was
secured with a silk suture and the lungs were subjected to manual lavage with 2 x 0.8 ml PBS.
Retrieved BALf samples were centrifuged at 1200 rpm, 10 min, at 4˚C and the supernatant
stored at -80˚C until use. Bronchoalveolar lavage samples were subject to glucose measure-
ment by E149C/A213R GBP-IANBD or Amplex red glucose oxidase assay (Thermo Fisher).
Standard curves were generated by adding known glucose concentration (from 0–10 mM) to
50 μl of either 0.3μM E149C/A213R GBP-IANBD or Amplex red reaction mix. Fluorescence
output was measured on a GloMax plate reader, excitation/emission 590/536 nm or 530/480
nm for E149C/A213R GBP-IANBD or Amplex red respectively.
For in vivo studies, mice (as above) were anaesthetised in Isoflurane 4–5% (O2 1.2 L/min),
held vertically and 50 μl of 0.3 μM E149C/A213R GBP-IANBD, 50 μl of positive control
(0.3 μM E149C/A213R GBP-IANBD pre-mixed with 10 mM D-glucose), or 50 μl of PBS vehi-
cle control were gently dropped by pipette onto one nostril for inhalation. Five minutes post
inhalation, mice were sacrificed as above and lungs were excised, frozen in optimal cutting
temperature compound (OCT) and 7 μm cryosections obtained. Images were then obtained
using a Nikon A1R confocal microscope using a 20x CFI plan fluor lens. As there is significant
auto fluorescence in lung tissue, spectra were acquired from the same emission window for
IANBD and lung tissue alone. The spectra associated with IANBD and autoflourescence were
then separated and artificially coloured on the acquired images (spectral un-mixing). Intensi-
ties were measured with ImageJ in regions surrounding the lumen for both the C57B/6 and
db/db mice. Animal Research Ethical approval was granted by Ethical committee in Gothen-
burg, Sweden (184–2012).
Results
As the wild-type E. coli GBP sequence does not contain a cysteine residue (C), single cysteine
substitutions were firstly made to enable thiol bonds to be formed with BADAN and the
IANBD fluorophore. Our aim was to produce a sensor with a Kd for glucose of ~1 mM and the
greatest dynamic range (Fmax/F0) possible.
Single amino acid substitutions to GBP labelled with BADAN
Phenylalanine at position 16 (F16) is located within the glucose binding pocket of GBP. The
change in protein conformation upon glucose binding exposes the F16 residue to less solvent.
Thus, it was anticipated that this would induce a change in fluorescence. As predicted, GBP
F16C-BADAN had a calculated Kd to D-glucose of 3.2 mM (R
2 = 0.98) but the fluorescence
dynamic range was small Fmax/F0 of 0.83 (Table 3, Fig 1a). The glutamine at position 140
(Q140) is located on one of the two lobes of GBP. Substitution with cysteine (Q140C) resulted
in no change in fluorescence emission with the addition of glucose and we were unable to cal-
culate a Kd. (Table 3). Glutamic acid at position 149 (E149) is located on the lip of the GBP
binding cleft. Previous studies had shown good fluorescence dynamic range for sensors with a
fluorophore attached to this residue [15,16]. E149C produced the largest fluorescent range of
all the single mutation sensors bound to BADAN with an Fmax/F0 of 0.97, and the Kd of the
sensor to D-glucose was too high at 84.2 mM (R2 = 0.98) (Table 3). The valine amino acid at
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position 207 is located within one of the lobes of the GBP. We were unable to gain a Kd and
dynamic range data for V207C GBP-BADAN (Table 3).
Single GBP substitutions labelled with IANBD
Each of the single mutant proteins was then labelled with the environmentally sensitive fluoro-
phore IANBD and the fluorescence in response to glucose measured. Of the four, the F16C
GBP mutant exhibited only a small increase in fluorescence with glucose binding with an
Fmax/F0 of 0.124, whereas the E149C GBP produced the largest change in fluorescence with an
Fmax/F0 of 1.96, and a Kd to D-glucose of 2.01 mM (R
2 = 0.98) (Table 3, Fig 1). Both the Q140C
and V207C mutants displayed negligible increases in fluorescence upon addition of glucose
with Fmax/F0 of 0.06 and 0.01 respectively (Table 3). As E149C produced the best Kd and Fmax/
F0 for D-glucose with both fluorophores we then introduced further amino acid substitutions
with an aim to increase the dynamic range (Fmax/F0).
Dual amino acid substitutions to GBP labelled with BADAN
Leucine (L238) is within close proximity to E149, (14.5Å in its open conformation and
12.8Å in its closed conformation). Although L238 is located near the binding cleft of the
protein, it makes no polar contact with the glucose molecule. Substituting leucine for serine
(S) created a double mutant E149C/L238S GBP-BADAN, which exhibited a Kd to D-glucose
of 1.6 mM (R2 = 0.93) but the dynamic range remained small Fmax/F0 of 0.98 (Table 3, Fig
2a). Alanine (A213) is also located in the same region in close proximity to E149 (11.8Å
when in the open conformation and 9.3Å apart when in the closed conformation) and
located near the binding cleft [17]. A213 was substituted with arginine (R). This has a
charged side chain which we predicted would result in a greater shift in the polarity of the
environment surrounding the fluorophore (See supporting information, S1 Fig). The double
mutant E149C/A213R GBP-BADAN had a Kd for D-glucose of 11.2 mM (R
2 = 0.94) and an
Fmax/F0 of 0.88 (Table 3, Fig 2b).
Table 3. Summary of the biochemical characteristics of GBP-labelled mutants.
Protein Fluorophore Kd (mM) R
2 Fmax/Fo
F16C BADAN 3.2 0.98 0.83
Q140C BADAN n/o n/o n/o
E149C BADAN 84.2 n/o 0.97
V207C BADAN n/o n/o n/o
F16C IANBD 3.2 0.98 0.124
Q140C IANBD 2.03 0.96 0.06
E149C IANBD 2.01 0.97 1.96
V207C IANBD n/o n/o n/o
E149C L238S BADAN 1.6 0.93 0.98
E149C A213R BADAN 11.2 0.98 0.88
E149C L238S IANBD 9.36 0.97 1.21
E149C A213R IANBD 1.01 0.91 5.8
E149C A213R Chromis 678 >190 0.90 n/o
E149C A213R Nile Blue n/o n/o n/o
Not obtained (n/o).
https://doi.org/10.1371/journal.pone.0254248.t003
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Dual amino acid substitutions to GBP labelled with IANBD
The dual mutant E149C/L238 GBP-IANBD had a calculated Kd for D-glucose of 9.36 mM
(R2 = 0.97) and Fmax/F0 of 1.21. Interestingly, the E149C/A213R GBP-IANBD Kd to D-glucose
of 1.02 mM (R2 = 0.91; n = 2) and an Fmax/F0 of 5.8 (Table 3, Fig 2c and 2d).
Fig 1. Fmax/F0 D-glucose concentration response curves for two single point GBP mutations. a. F16C labelled
with BADAN and b. E149C labelled with IANBD. Curves were fitted using the one site-specific binding with Hill slope
formulae in GraphPad prism.
https://doi.org/10.1371/journal.pone.0254248.g001
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As the E149C/A213R GBP sensor produced the largest Fmax/F0 when labelled with IANBD
and had a Kd for D-glucose in the concentration range ideal for measuring ASL glucose, the
protein was selected to label with longer wavelength fluorophores for potential future in vivo
applications.
Dual amino acid substitutions to GBP labelled with Chromis 678 or Nile
Blue
E149C/A213R GBP labelled with Chromis 678 produced a sensor with a Kd for D-glucose of
190 mM (R2 = 0.9) and an Fmax/F0 of 1.43 over the glucose concentration range tested. This
was a smaller fluorescence range and larger Kd than when the protein was labelled with
IANBD. Attaching Nile blue to the mutant GBP resulted in no glucose-dependent fluorescence
(Table 3, Fig 3).
Fig 2. Fmax/F0 D-glucose concentration response curves for each of the dual mutation GBPs. a. E149C/L238S and b. E149C/
A213R labelled with BADAN, c. E149C/L238S and d. E149C/A213R labelled with IANBD. Curves were fitted using the one site-
specific binding with Hill slope formulae in GraphPad prism.
https://doi.org/10.1371/journal.pone.0254248.g002
PLOS ONE A modified fluorescent glucose sensor
PLOS ONE | https://doi.org/10.1371/journal.pone.0254248 July 9, 2021 8 / 19
Selectivity of E149C/A231R GBP-IANBD for D-glucose
As labelling with the longer wavelength fluorophores resulted in a decrease in fluorescence
range, the best sensor we produced was E149C/A213R GBP-IANBD. Introducing mutations
can have an effect on the specificity of the protein to sugars. Therefore, we investigated changes
in fluorescence in the presence of L-glucose (enantiomer of D-glucose) and D-fructose which
is found in small quantities in the ASL. In concentrations up to 20 mM (a concentration which
is significantly higher than that found in the airways), the addition of L-glucose or D-fructose
to the E149C/A213R GBP-IANBD sensor did not result in a change in fluorescence, indicating
that the protein was selective for D-glucose (Fig 4).
Fig 3. Fmax/F0 D-glucose concentration response curve for the dual mutant E149C/A213R GBP labelled with
Chromis 678. The curve was fitted using the one site-specific binding with Hill slope formulae in GraphPad prism.
https://doi.org/10.1371/journal.pone.0254248.g003
Fig 4. Fluorescence associated with bound fraction of E149C/A213R GBP-IANBD with increased concentration
of D-glucose (circles) compared to L-Glucose (squares) and D-fructose (triangles). The curve for D-glucose was
fitted using the one site-specific binding with Hill slope formulae in GraphPad prism. Curves could not be fitted for L-
glucose or D-fructose.
https://doi.org/10.1371/journal.pone.0254248.g004
PLOS ONE A modified fluorescent glucose sensor
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In vitro application of E149C/A213R GBP- IANBD
We took two approaches in vitro. First, we applied the sensor to the apical/luminal surface of
H441 and HBEC airway calls grown at air-liquid interface to see if we could detect changes in
the airway surface liquid (ASL) glucose concentration with a hyperglycaemic challenge. We
measured fluorescence of E149C/A213R GBP-IANBD when applied with known concentra-
tions of D-glucose to the ASL of HBEC and H441 grown on transwells. Settings were opti-
mised differently for HBEC and H441 due to the differences in monolayer thickness and ASL
heights in these cell types. Fluorescence increased with glucose concentration in the ASL (Fig
5a and 5c). However, over the same concentration range the change in IANBD fluorescence
in both cases appeared reduced when compared to that measured in PBS. Then we applied
Fig 5. Fluorescence of E149C/A213R GBP-IANBD applied to the ASL of HBEC or H441 grown at air-liquid-interface together with
known concentrations of glucose to obtain a concentration effect curve a. and c. The response curve measured in PBS over the same
glucose concentration range is shown as a dotted line in both graphs. Fluorescence of E149C/A213R GBP-IANBD applied to the ASL of
HBEC or H441 without added glucose to measure changes in ASL glucose when basolateral glucose concentration was raised from 5mM to
15 mM D-glucose in the basolateral chamber for 10 minutes b. and d. Data are shown as mean ± SD. Significantly different �� p<0.001, ����
p<0.0001.
https://doi.org/10.1371/journal.pone.0254248.g005
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E149C/A213R GBP-IANBD without added glucose to measure fluorescence in the ASL when
the D-glucose concentration of the basolateral/serosal bath was increased from 5 to 15 mM.
Fluorescence increased by from 16126 ± 1045 to 25138 ± 1593 relative fluorescence units
(RFU) (p� 0.0001; n = 10) in HBEC cells and from 1209 ± 639 to 3370 ± 1132 RFU (p� 0.001;
n = 8) in H441 respectively (Fig 5b & 5d). Resolving the mean change in fluorescence using
the concentration effect curves indicated an estimated change in glucose concentration in the
ASL from 0.2±0.1 to 4.3±2.1 mM in HBEC and 0.7 ± 0.7 to 5.8 ± 2.5 mM in H441 cells when
basolateral glucose was increased from 5–15 mM (p<0.0001, n = 10 and 8 respectively).
Second, we investigated the potential of E149C/A213R GBP-IANBD for observing changes
in glucose concentration in the ASL by microscopic imaging. Confocal X-Z images of the cells
clearly captured IANBD and dextran-tetramethylrhodamine (TMR) fluorescence in the ASL
overlying the epithelial cells (Fig 6a). The fluorescence of E149C/A213R GBP-IANBD but not
TMR was increased when basolateral D-glucose was raised from 5 to 15 mM. IANBD/TMR
fluorescence intensity ratio increased from 21.7±5.2 (n = 4) to 30.6±5.3 (n = 5) (p� 0.05) at
10 minutes (Fig 6b). Taken together, these data indicate that increasing basolateral glucose
increased glucose in the ASL which is sensed by E149C/A213R GBP-IANBD. Finally, using
the fluorimeter protocol, we analysed the fluorescence stability of E149C/A213R GBP-IANBD
applied to the apical surface of H441 grown at air-liquid-interface with either 5 mM or after
raising to 15 mM D-glucose in the basolateral chamber for up to 300 minutes. Fluorescence
did not decline over time and remained relatively stable in cells exposed to 15mM glucose. It
increased in cells exposed to 5mM glucose but values did not converge (Fig 6c).
Bronchoalveolar lavage fluid (BALf)
After confirmation that the sensor increased fluorescent output in response to glucose in vitro,
application of the sensor was progressed into murine models of normoglycaemia (wildtype
C57Bl/6) and hyperglycaemia (db/db). Blood glucose was higher in db/db (32.65 ± 0.93 mmol/
L) compared to C57Bl/6 (8.64 ± 0.68 mmol/L) (p� 0.0001; n = 12) (Fig 7a). For 9 of the db/db
mice, blood glucose exceeded the limit of detection of the Accu-Chek1 set at 33.3 mmol/L.
We collected bronchoalveolar lavage fluid (BALf) from these mice (which contains diluted
ASL). Glucose concentration in BALf by Amplex1 red glucose oxidase assay was 40.3 ±
5.7 μM and 77.1 ± 18.8 μM (p� 0.01; n = 6) for the wildtype and hyperglycaemic db/db mice
respectively (Fig 7b). The glucose concentration using E149C/A213R GBP-IANBD in db/db
mice was 170.4 ± 95.4 μM (calculated using a dose response curve for the glucose sensor in
PBS) (Fig 7c & 7d). We were unable to detect changes in fluorescence in BALfs from C57Bl/6
mice and thus unable to calculate glucose concentration.
Direct application of the sensor to the ASL in vivo
As BALf contains highly diluted ASL, we investigated whether we could detect changes in glu-
cose with E149C/A213R GBP-IANBD applied directly to the lung lumen. Unfortunately, the
wavelength of IANBD has limited tissue penetration for direct in vivo imaging using some
methodologies although two photon imaging is a possibility. Therefore, we tried to see if we
could detect changes in luminal fluorescence in cryosections of lungs after mice had inhaled
E149C/A213R GBP-IANBD. The lung has significant innate fluorescence so we used spectral
un-mixing to separate IANBD fluorescence from tissue auto-fluorescence and the images were
coloured accordingly (Fig 8a). E149C/A213R GBP-IANBD fluorescence was greater in hyper-
glycaemic db/db mice with a mean intensity of 436.0 ± 131.9 units (n = 12) than in normogly-
caemic C57B/6 mice 119.9 ± 171.9 units (n = 12) (p�0.05). Both C57B/6 and db/db mice
had a higher E149C/A213R GBP-IANBD fluorescence intensity than the vehicle control
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(-284.6 ± 187.7 units, n = 12; p�0.05 and p�0.0001, respectively). Neither the db/db or C57B/
6 intensities differed from the positive control of the sensor pre-bound with D-glucose prior
to inhalation (Fig 8b). It was not possible to determine actual glucose concentration from this
fluorescence data because we were unable to construct an appropriate dose response curve.
Discussion
We previously generated a sensor H152C/A213R GBP-BADAN with a Kd for D-glucose of ~1
mM to measure glucose concentration in airway surface liquid (ASL) [18]. However, this was
not suitable for work in vivo. Our aim was therefore, to further modify GBP and obtain a better
Fig 6. Exemplar confocal XZ images of HBEC cells grown at air-liquid interface stained with Hoechst (blue) to label nuclei, dextran
tetramethylrhodamine (TMR, red) to label airway surface liquid (ASL) and E149C/A213R GBP-IANBD (GBP-IANBD, green) in ASL. A merged
image (Merge) in which the overlay of TMR and GBP-IANBD appears as yellow. Images were collected from cells exposed to 5 mM or after raising to
15 mM D-glucose in the basolateral chamber for 10 minutes. b. Collated confocal data of ASL fluorescence ratio (GBP-IANBD/TMR) for HBEC shown
in a. Data are shown as mean ± SD. Significantly different � p<0.05. c. Change in fluorescence of E149C/A213R GBP-IANBD applied to the apical
surface of H441 grown at air-liquid-interface with either 5 mM or after raising to 15 mM D-glucose in the basolateral chamber for up to 300 minutes
measured by fluorimeter. A size bar (10μm) applicable to all images is shown in the top left-hand image.
https://doi.org/10.1371/journal.pone.0254248.g006
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sensor for this purpose. Several new mutations to GBP were investigated. Of these, the F16C
GBP-BADAN gave the best readouts with a Kd to D-glucose of 3.2 mM and a respectable fluo-
rescence dynamic range (Fmax/F0) of 0.83. However, E149C GBP was more useful for the lon-
ger wavelength fluorophore IANBD with a Kd to D-glucose of 2.01 mM and an Fmax/F0 of
1.96. These data are consistent with previous work from ourselves and others which show that
the efficacy of the mutation in the GBP is not only dependent on its position relative to the glu-
cose binding site but also how it interacts with the fluorophore and the solvent environment
surrounding it [18,19].
Further mutations identified E149C/A213R GBP-IANBD with a Kd for D-glucose of 1.02
mM and a fluorescence dynamic range of 5.8. The success of this candidate most likely lay in
the positions and properties of the two mutations. E149C, as it is close to the binding site,
Fig 7. a. Blood glucose concentration (mmol/L), Bronchoalveolar lavage (BAL) glucose concentration measured by b.
glucose oxidase assay and c. E149C/A213R GBP-IANBD for C57Bl/6 and db/db mice used in study. Data are shown as
mean ± SD. Significantly different �� p<0.01, ���� p<0.0001. d. E149C/A213R GBP-IANBD fluorescence/D-glucose
concentration curve. Data were fitted with a curve using Graphpad prism.
https://doi.org/10.1371/journal.pone.0254248.g007
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would likely affect the affinity for D-glucose, and A213R introduces a charged amino acid in
close proximity to where the environmentally sensitive fluorophore is bound (within 11.8 Å
when not bound to glucose and 9.3 Å when bound), altering the polarity of the environment
and thus the fluorescent output (See supporting information, S1 Fig).
The longest wavelength fluorophore we could obtain, that worked with GBP for effective
glucose sensing was IANBD with an emission wavelength maximum of 536 nm. This sensor
was specific for D-glucose and exhibited fluorescence stability in experiments lasting up to 6
Fig 8. Exemplar images showing spectral un-mixing of cryo-sectioned C57Bl/6 (wild type) lungs treated with a.
vehicle and b. E149C/A213R GBP-IANBD. Artificially coloured IANBD emission spectra collected from the sample
(green), and artificially coloured lung tissue spectra (blue). Scale bar is 20 μm. Fluorescence intensity of E149C/A213R
GBP-IANBD spectra surrounding the luminal regions were measured with ImageJ. c. collated data of fluorescence
intensity of cryo-sections from C57Bl/6 or db/db mice treated with E149C/A213R GBP-IANBD, or C57Bl/6 treated
with vehicle, or C57Bl/6 treated with E149C/A213R GBP-IANBD pre-bound with 10 mM D-glucose (+ve control).
Data are shown as mean ± SD. Significantly different � p<0.05, ��� p<0.001, ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0254248.g008
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hours. Ideally, for a broadly applicable and effective in vivo sensor, the emission wavelength
needs to be 650 nm– 900 nm to penetrate tissue as these wavelengths are minimally absorbed
by haemoglobin and water [20,21]. The fluorophores Chromis 678 and Nile blue have emis-
sion maxima that sit within this window (Emmax 701 nm and 670 nm respectively). Binding of
Chromis 678 to E149C/A213R GBP resulted in a very large increase in the Kd for D-glucose
(<190 mM), indicating a significant hindrance of glucose binding to GBP. A similar effect of
Chromis 678 was observed when bound to H152C/A213R GBP [18] and the H152 residue lies
in close proximity to the E149 residue used in this study. Chromis 678 is larger than IANBD
and has 4 benzene rings as opposed to one in IANBD. Thus, its size/structure likely impedes
the glucose biding site. Nile blue bound to E149C/A213R GBP did not exhibit a change in fluo-
rescence in response to glucose. Nile blue can produce strong dipole moments depending on
the polarity of its surroundings making it a good environmentally sensitive dye [22]. Whilst
Nile Blue had been shown to exhibit a change in fluorescence when bound to a different GBP
mutant, this and our previous data indicate that long wavelength fluorophores bound to GBP
consistently exhibit Fmax/F0 that currently are too low to be of practical use in the measure-
ment of ASL glucose [18,23]. The use of quantitative structure activity relationship (QSAR)
and docking study simulations of these mutants could help us design better long wavelength
GBP sensors in the future.
In vitro, it has been shown that exposure of H441 cells and HBEC exhibited a rise in glucose
on the apical surface when basolateral glucose was increased [9,19]. Measurement of glucose
concentration in ASL is challenging because ASL volume is small and dynamically regulated
by airway cells. We used L-glucose to control for the osmotic effects of raising D-glucose
concentration. We also used TMR as a volume marker in confocal experiments and for ratio
metric analysis with E149C/A213R GBP-IANBD because we previously showed that the fluo-
rescence of TMR did not change in response to glucose [18]. We chose a consistent concentra-
tion of E149C/A213R GBP-IANBD and TMR to achieve the best fluorescent output but
recognise there are limitations associated with potential concentration dependence differences
in fluorescent output of IANBD and TMR.
Nevertheless, the use of E149C/A213R GBP-IANBD in the ASL showed an increase in
IANBD fluorescence compared to TMR 10 minutes after raising basolateral glucose. This was
more rapid than that previously reported for a BADAN labelled GBP, which conveyed changes
after a two hour exposure [18]. In addition, fluorescent analysis of XZ sections by confocal
microscopy using this ratio metric method gave similar outcomes and similar changes in
relative fluorescence to that of fluorometric analysis of E149C/A213R GBP-IANBD applied
alone to the ASL when basolateral glucose was raised from 5 to 15 mM. As E149C/A213R
GBP-IANBD is specific, rapid and stable we suggest it could be a better sensor for interrogat-
ing epithelial regulation of ASL glucose.
In support of this notion, the sensor revealed a difference in the fluorescence emission in
response to increased basolateral glucose in H441 and HBEC. There was a bigger change in
H441 cells than HBEC and the variability of the HBEC data was smaller than that of H441.
Using known glucose concentrations applied to the ASL we constructed dose response curves.
Resolving the glucose concentrations for the ASL showed a similar trend between H441 and
HBEC and values were consistent with previous findings [9,24,25]. These differences are likely
related to the typically lower TEER of H441 compared to HBEC (~300 Ocm2 and ~800 Ocm2,
respectively) and thus a potentially higher transepithelial permeability to glucose of H441.
Differences in glucose transporters and their distribution (GLUT2 and 10 in H441 and
GLUT1,2,4 and 10 in HBEC), uptake and metabolism between the cell types could also result
in tighter control of glucose movement into and out of the ASL by HBEC [6,19,24,26–29].
Interestingly the dose response curves in ASL were slightly shifted to the right compared to
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those measured in PBS indicating that factors in ASL might temper sensor fluorescence. ASL
pH of 7.1–7.2 was not altered in NHBE when exposed to elevated glucose, binding of acrylo-
dan bound GBP was stable in the pH range 6.5–8.0 [30] and IANBD is stable at pH7.0. How-
ever, ASL viscosity could influence calibrations and this requires further investigation.
When used to measure glucose concentration in BALf, there were limits in the sensitivity of
the sensor. Consistent with previous findings, db/db mice had higher blood glucose and more
glucose in their lungs compared to wildtype mice as measured by glucose oxidase assay and
fluorescence emission from E149C/A213R GBP-IANBD [31]. However, no fluorescence above
baseline was detected with the sensor in wildtype BALf indicating a lack of glucose. During
BAL the constituents of the ASL, including glucose, are significantly diluted. Very low concen-
trations of glucose can be detected in enzymatic assays which amplify the signal in a non-
reversible end point reaction. The GBP sensor, on the other hand, reacts in a reversible 1:1
ratio with glucose, and this may limit its sensitivity in comparison. In this study, Amplex red
assay glucose concentration in the BALf of wildtype mice was 33 μM. At this concentration,
the change E149C/A213R GBP-IANBD fluorescence would be negligible, and thus, the sensi-
tivity of the sensor may be limited in this scenario.
In vivo imaging in lungs is challenging. As a proof of concept we delivered E149C/A213R
GBP-IANBD to normal and diabetic mouse lungs by inhalation to see if we could determine
differences in luminal glucose concentration. This part of the study had a number of limita-
tions. The distribution/fractionation of the sensor across the lung can be affected by respira-
tory rate which is reduced by anaesthesia and reportedly reduced by hyperglycaemia [32]. The
emission wavelength of IANBD did not allow for imaging in whole tissue and it is close to that
of lung tissue autofluorescence. Therefore, we used cryosections and spectral unmixing to gen-
erate images of the distal lung. The E149C/A213R GBP-IANBD fluorescence we detected in
luminal regions of the lung indicated that, in accordance with other studies, nasal inhalation
was sufficient to get the sensor to the distal lung [33–35]. However, we could not clearly dem-
onstrate that fluorescence was associated with ASL. Whilst we were able to show higher sensor
fluorescence in hyperglycaemic compared to normal mice we cannot be certain that the glu-
cose was derived from ASL and not plasma/interstitial fluid leak from the process of cryo-sec-
tioning. As E149C/A213R GBP-IANBD output from normal and hyperglycaemic sections
were similar to that using sensor pre-bound with 10 mM glucose indicated that this may have
been the case. It is also conceivable that glucose in the ASL of mice is higher than that reported
for human airway secretions [36]. Nevertheless, our data provide proof of concept for the
potential use of such glucose sensors in the lungs in vivo.
In conclusion, we have developed a longer wavelength glucose sensor E149C/A213R
GBP-IANBD that can be used to directly image and measure glucose concentration in ASL in
vitro. We have shown that the sensor can be delivered to the lung lumen and that the sensor
reports differences in glucose concentration in the lungs of normoglycaemic vs hyperglycae-
mic mice although it remained unclear if the glucose was derived solely from ASL in vivo. Fur-
ther detailed validation is now required but we propose that this sensor provides a novel tool
for development to measure changes in glucose concentration in models of lung diseases.
Supporting information
S1 Fig. E. coli GBP with the E149 residue highlighted in red and the A213 residue
highlighted in orange. a- The protein in its open conformation in the absence of glucose. b-
The protein in its closed conformation in the absence of glucose. Figure b has been rotated 90˚
along the y-axis compared to figure a.
(TIF)
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